Search the record

Health the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [17274/26

IPHA Framework Agreement which aims for a 180-day decision timeline are being applied to the HSE’s consideration of Skyclarys, to prevent further delays; and if she will make a statement on the matter. [17275/26

Deputy Ryan O'Meara asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which can currently be classed as having an ‘unmet need

Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims

Health the specific steps being taken to ensure the HSE considers the “time-critical” nature of FA during the current price negotiations for Skyclarys. [17453/26

Deputy Michael Lowry asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease (details supplied) which currently can be classed as having an ‘unmet

Deputy Denise Mitchell asked the Minister for Health if consideration will be given to making the medication Skyclarys (omaveloxolone) available to Irish Friedreich’s Ataxia patients under the current drugs reimbursement process; if she recognises the clinical necessity of this request as this drug is the only proven

Deputy Barry Heneghan asked the Minister for Health when Skyclarys (omaveloxolone), the first approved treatment for Friedreich’s ataxia, will be made available to patients in Ireland through reimbursement; if she will prioritise the assessment and reimbursement process given the urgent clinical need for the approximately 200 people

Deputy Peter 'Chap' Cleere asked the Minister for Health if the medicine skyclaris/ omaveloxalone will be reimbursed by the HSE as it is the only drug approved to treat Freidreicsh’s ataxia; and if she will make a statement on the matter. [11491/26

Deputy Martin Daly asked the Minister for Health if there are plans to introduce skyclarys (omaveloxolone) into the Irish market for the treatment of Friedreich's ataxia in adults and adolescents; which is approved in America, Canada, UK, some European countries but not Ireland to date